Alkermes reports Q3 2026 financial results

Item 2.02 Results of Operatio ns and Financial Condition.

On November 3, 2026, Alkermes plc (the "Company") announced financial results for the three and nine months ended September 30, 2026. Copies of the related press release and the investor presentation to be displayed during the Company's conference call on November 3, 2026 discussing such financial results are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively.¹ This information, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Sta tements and Exhibits.

(d) Exhibits

EXHIBIT INDEX⁵

Exhibit No.

Description

99.1⁵

Press release issued by Alkermes plc on November 3, 2026 announcing financial results for the three and nine months ended September 30, 2026.⁵

99.2

Investor presentation to be displayed by Alkermes plc on November 3, 2026.

104

Cover page interactive data file (embedded within the Inline XBRL document).

2

SIGNA TURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALKERMES PLC

Date: November 3, 2026

By:

/s/ Joshua Reed

Joshua Reed

Senior Vice President, Chief Financial Officer (Principal Financial Officer)

3

Alkermes Contacts:

For Investors:

Alkermes plc Reports Third Quarter 2026 Financial Results²

— Third Quarter Revenues of $480.1 Million —²

— GAAP Net Income of $16.3 Million and Adjusted EBITDA of $120.1 Million —³

— Company Reiterates 2026 Financial Expectations —⁴

DUBLIN, Nov. 3, 2026 — Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2026.

"We delivered solid commercial and financial performance in the third quarter while continuing to advance our portfolio of orexin 2 receptor agonists in central disorders of hypersomnolence and other neuropsychiatric conditions,⁶" said Blair Jackson, President and Chief Executive Officer of Alkermes. "The rapid expansion of our orexin development programs, highlighted by our recent clinical proof-of-concept data in ADHD and initiation of a phase 2 study in major depressive disorder, further strengthens our leadership position in orexin-based research.⁷ As we continue to advance our orexin development portfolio, we are growing the body of evidence supporting the potential of orexin biology across multiple neuropsychiatric disorders and expect several